Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial
Authors:
- 11 July 2011
- journal article
- research article
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 15 (3) , 229-241
Abstract
Objectives. This study was designed to investigate whether a preventive weight management program (WMP) reduces weight gain during olanzapine (OLZ) treatment. Moreover, we examined the effects of intervention on metabolic parameters. Methods. Patients (N = 100) with schizophrenia or schizoaffective disorder (DSM-IV) who had commenced treatment with OLZ were recruited. Following a run-in period of 4 weeks, 74 patients who had gained at least 1.5 kg body weight were randomized to receive either 12 bi-weekly WMP sessions (prevention group (PG), n = 36), or usual care (control group (CG), n = 38). Anthropometric and metabolic parameters were assessed after the 24-week intervention phase and a 24-week follow-up. Results. Forty-two percent of 74 participants (PG: 36.1%, CG: 47.4%) finished the 24-week intervention phase while 34% of them (PG: 30.6%, CG: 36.8%) completed the 48-week study. There was no significant difference in weight gain between groups (PG: + 3.4 ± 4.2 kg vs. CG: + 4.5 ± 6.1 kg, P = 0.184) after 24 weeks. Nevertheless, PG showed a significantly smaller increase in waist circumference than CG (PG: + 4.6 ± 8.3 cm, CG: + 10.1 ± 7.3 cm, P = 0.019) after 48 weeks. Furthermore, PG showed a significantly smaller increase in fasting glucose (P = 0.031) and 2-h glucose after oral glucose load (P = 0.018) than CG. Conclusions. These results suggest that preventive WMP may reduce the risk of abdominal obesity and deterioration of glucose metabolism in OLZ-treated patients.Keywords
This publication has 40 references indexed in Scilit:
- Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trialSchizophrenia Research, 2010
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and AdolescentsJAMA, 2009
- Effects of a 10‐week weight control program on obese patients with schizophrenia or schizoaffective disorder: A 12‐month follow upPsychiatry and Clinical Neurosciences, 2009
- Möglichkeiten des Gewichtsmanagements in der Behandlung schizophrener Psychosen mit atypischen AntipsychotikaFortschritte der Neurologie · Psychiatrie, 2008
- Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomised controlled trialsThe British Journal of Psychiatry, 2008
- Comorbid Somatic Illnesses in Patients With Severe Mental DisordersThe Journal of Clinical Psychiatry, 2008
- Medication-Induced Weight Gain and Dyslipidemia in Patients With SchizophreniaAmerican Journal of Psychiatry, 2006
- Attenuation of Antipsychotic-Induced Weight Gain With Early Behavioral Intervention in Drug-Naive First-Episode Psychosis PatientsThe Journal of Clinical Psychiatry, 2006
- Gewichtsveränderungen unter Therapie mit PsychopharmakaFortschritte der Neurologie · Psychiatrie, 2006
- Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophreniaBMC Psychiatry, 2005